Strategic partnerships Nanexa collaborates with major pharma players including AstraZeneca and recently signed a license and option agreement with Moderna, indicating a strong openness to co-development and licensing deals that can be expanded with additional biotech and big pharma partners.

Late-stage interest The company was named a finalist in the Drug Delivery Technology category by Fierce Life Sciences and has an upcoming appearance at ADA Congress, signaling industry recognition and opportunities to engage with clinicians and researchers on its long-acting injectable delivery platform.

Leadership expansion Recent executive addition of a seasoned Chief Business Officer with over 25 years in life sciences suggests a ramp in business development, licensing negotiations, and strategic partnerships, creating a ready-to-engage champion for external opportunities.

Funding momentum A notable USD 750k financing round in 2025 indicates investor interest and potential for grant-ready or co-development funding options, which can be leveraged to pursue joint ventures or milestone-driven collaborations.

Clinical and PK focus Nanexa’s PharmaShell platform and ongoing PK data for NEX-20 highlight a track record in targeted long-acting drug delivery, presenting selling points for conversations with oncology, immunology, and other indications where sustained release can improve therapeutic profiles.